Psychedelic Alpha’s Josh Hardman speaks with Compass Pathways CEO, Kabir Nath, about a range of topics: from the company’s recently-announced agreements that could shed light on what the roll-out of COMP360 psilocybin therapy might look like, through to the motivation behind its distinctive ‘psychological support’ model and Nath’s thoughts on a competitor’s fast follower strategy.


Previous articlePT482 – Behind the Scenes: A Conversation on Psychedelic Business, Media, and Education
Next articleCaught in the Act: A Chemist’s Battle Against Felony Drug Charges